Johnson & Johnson's Tecvayli receives EU approval for multiple myeloma

The European Commission has approved an expanded indication for Johnson & Johnson’s TECVAYLI (teclistamab) in combination with daratumumab. This treatment is intended for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior treatment.

The combination therapy utilizes complementary mechanisms of action: daratumumab modulates the immune system and enhances T-cell fitness and activation, which amplifies the elimination of myeloma cells mediated by teclistamab. This approval introduces a new therapeutic option as early as the second line of treatment for RRMM patients.

Medical professionals note that the combination has demonstrated relevant improvements in progression-free survival and overall survival, while also offering the potential to reduce the use of corticosteroids in treatment regimens.